Articles On Bionomics (ASX:BNO)

Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app   Health Check is renowned biotech journo Tim Boreham’s daily...

Bionomics (ASX:BNO) has announced positive topline results from its Phase 2b ATTUNE trial of BNC210 for the treatment of Post-Traumatic Stress Disorder (PTSD).

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive sympt...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX 200 benchmark ends big day of earnings near parity, Small Ordinaries (XSO) climbs 0.5% Tech Sector surge offset by Consumer stocks and Energy  Small cap gains led by resources and explorer names, WYX continues climb    Just an enormou...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

 The ASX 200 benchmark has climbed down from highs at lunch to finish on +0.39%. Health Care was well out in front of the market all day, thanks to a chunky bump for CSL. Voltaic Strategic Resources won the Small Caps Cup, rising 22.5% for...

ASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and InfoTech tried their best, but the overall gloom was too much to fight. Lithium Universe (ASX:LU7) banks a solid market debut as it kicks off i...

ASX sleepwalks to an underwhelming -0.3% loss for the day.  Real Estate the ‘highlight’, on a paltry +0.5% Lithium Australia’s tech-for-facilities deal with MinRes saw it climb past +80% for the session.   It’s been a weak and sorry day o...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 has had its worst day in roughly a month with a 1.29 percentage dip  The sectors were a shade of spilt claret, with Utilities and Real Estate leading losses Standout small caps: BCAL Diagnostics and American West Metals   Loca...

The ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the RBA Sectors were a green scene, with IT and Staples leading the way Standout small caps: Viridis, Imricor and Baby Bunting, among several ot...

The ASX couldn’t make up its mind, a bit like economists looking ahead to the RBA decision tomorrow. Health Care and Industrials Stocks had a day to savour, while Staples and IT largely did not. Some standout small caps: TALi Digital, Ecof...

The ASX 200 put on a much better show today, with a +0.46% gain at closing time Sectors wise, Materials turned yesterday’s frown upside down Notable performers today: Pilbara Minerals; DXN; Si6 Metals; Strickland Metals   It’s been a much...

Bod Science to go ahead with Aqua Phase acquisition after study results Osteopore to ramp up China business after $10m partnership deal Bionomics to delist from the ASX   Bod Science’s study supports acquisition of Aqua Phase Cannabis foc...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX 200 closed -0.10% in the red today, after feeling flat all day Sectors wise, Energy stocks carried the torch with enthusiasm, while Materials wasn’t let anywhere near said torch Notable performers today: pharma stock Telix (ASX:TLX...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Amid the hype about using artificial intelligence (AI) for anything from robotic call centres to writing biotechnology columns, Control Bionics’ (ASX:CBL) new chief executive Jeremy Steele is sceptical about the use of technology for techno...

The S&P ASX 200 closes down 0.2%, while the S&P XEC fell 0.61 Larvotto Resources and OD6 Metals both rises after positive rare earths drilling results VHM appoints Mineral Technologies (Downer) for plant cost estimate on Goschen ra...

The ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soared ~3.0% because someone missed a memo. Besra Gold is back on top with a 36% leap after Quantum’s cheque cleared customs.   Local markets w...

Aussie bourse has worst day since November 3 with S&P ASX 200 down 2.28% Even darling lithium stocks are down on declining prices in China Magnum Mining & Exploration soars 60% on positive metallurgical test work So it’s Friday...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX 200 adds just 0.1% because it was literally the least it could do. Aussie tech stock surge negated by Doctors and Miners having a bad hair day. Two ASX-listed lithium players are under attack over alleged corruption in Africa, of all p...

Bionomics (ASX:BNO) has announced the release of an analysis of the data from its Phase 2 PREVAIL study evaluating the efficacy and safety of BNC210 for the treatment of acute Social Anxiety Disorder.

ASX scuttled by bleak rates outlook in the US, down 0.83% for the day RBA boss Philip Lowe had better news for Aussies. Kind of Summit Resources galloped to a win, up 35% on great REE news at Stallion   We have comments from US Fed chair...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p...

Bionomics (ASX:BNO) has announced the results from its Phase 2 PREVAIL study to evaluate the safety, tolerability, and efficacy of BNC210 for the acute treatment of Social Anxiety Disorder.

The ASX 200 was in the red again, down 0.21% today 9 out 11 sectors finished lower led by Real Estate, with Energy and Materials gaining Stockmarkets head into the festive period in a downbeat mood, Oanda says   The ASX 200 was down 0.21%...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Biopharmaceutical company, Bionomics (BNO), appoints neuroscientist Dr Spyros Papapetropoulos (MD) as its new President and Chief Executive OfficerDr Papapetropoulos will step into the role on January 5, 2023, which will see him receive US$...

Respiri’s wheezo RPM will be installed in New Mexico, USA Beamtree signs new distributor Bionomics welcomes new CEO   Respiri (ASX:RSH) has secured another primary care practice, Hand Family Healthcare, located in Clovis, New Mexico, USA....

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Bionomics (ASX:BNO) has announced the pricing of an underwritten follow-on offering in the US of 641,026 American Depositary Shares, each representing 180 ordinary shares of the company, at a public offering price of US$7.80 per ADS...

OMG, Tuesdays, amirite? There’s been a lot of info flying around the newsroom today, and a fair bit happening in other places as well, so here’s a flying recap of all the bits that we reckon might have flown under your radar and hit you fai...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.  In this episode Tim chats to Dr Errol De Souza, executive chairman a...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

Paradigm Biopharmaceuticals’ (ASX:PAR) investment relations guy Simon White is a bit different to your average biotech corporate gun for hire, given he’s actually tried the remedy he is promoting. A footballer with the AFL’s Carlton Footbal...

Gold aspirant Cavalier Resources announces its new substantial shareholders following IPO Gold stocks in demand as investors seek the traditional inflationary hedge Hard hit health and e-commerce stocks continue to lose substantial shareho...